日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors

Givastomig（一种 CLDN18.2 和 4-1BB 双特异性抗体）作为单药疗法治疗 CLDN18.2 阳性晚期或转移性实体瘤患者的首次人体研究

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-4280
Ku, Geoffrey; Shen, Lin; Dayyani, Farshid; Kratz, Jeremy; Liang, Xinjun; Liu, Funan; Wang, Zhenning; Feller, Laura; Girda, Eugenia; Pan, Hongming; Kim, Sunnie; Deng, Yanhong; Deng, Ting; Liu, Tianshu; Powderly, John; Spencer, Kristen; Schneider, Reva; Berlin, Jordan; Xu, Claire Cong; Ahlers, Christoph M; Liu, Xuejun; Chung, Jou-Ku; Sabbatini, Peter; Park, Jinyoung; Lim, Yangmi; Jeon, Juyeun; Meng, Yuan; Klempner, Samuel J
CLDN1
Human
发表日期：2025
文献求助 收藏

First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors

首次人体 I 期开放标签研究，评估抗 TIM-3 单克隆抗体 INCAGN02390 对特定晚期或转移性实体瘤患者的疗效

期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyaf144
Gutierrez, Martin E; Tang, Shou-Ching; Powderly, John D 2nd; Balmanoukian, Ani S; Hoyle, Paul E; Dong, Zhiwan; Cheng, Lulu; Gong, Xiaohua; Janik, John E; Bourayou, Nawel; Hamid, Omid
单克隆抗体
TIM
发表日期：2025
文献求助 收藏

First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors

首次人体 I 期开放标签研究，评估 LAG-3 拮抗剂抗体 INCAGN02385 在特定晚期或转移性实体瘤患者中的疗效

期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyaf136
Powderly, John D 2nd; Gutierrez, Martin E; Balmanoukian, Ani S; Hoyle, Paul E; Dong, Zhiwan; Cheng, Lulu; Chen, Xuejun; Janik, John E; Bourayou, Nawel; Hamid, Omid
发表日期：2025
文献求助 收藏

Mapping the Geographic Distribution of Dimorphic Mycoses Using a US Commercial Insurance Database

利用美国商业保险数据库绘制二型真菌病的地理分布图

期刊:Open Forum Infectious Diseases
影响因子:3.8
doi:10.1093/ofid/ofae755
Goodman, Reid; Rauseo, Adriana M; Windham, Samuel L; Zuniga-Moya, Julio C; Powderly, William G; Spec, Andrej; Mazi, Patrick B
微生物学
发表日期：2025
文献求助 收藏

SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial

SARS-CoV-2 N 蛋白和抗刺突蛋白血清学：对 COVID-19 疾病严重程度和死亡率的深入了解——ACTIV-1 试验的二次分析

期刊:Therapeutic Advances in Infectious Disease
影响因子:3.4
doi:10.1177/20499361251333617
Mena Lora, Alfredo J; Enders, Kimi; Wu, Huimin; Parra-Rodriguez, Luis; Palma, Christopher; Saliba, Katy; Laverdurre, Sylvain; Smith, P Brian; Anstrom, Kevin J; Bozzette, Samuel A; Powderly, William G
SARS-CoV-2
发表日期：2025
文献求助 收藏

IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

IPH5201，一种抗CD39单克隆抗体，可作为单药疗法或与度伐利尤单抗联合用于治疗晚期实体瘤。

期刊:Cancer Research Communications
影响因子:3.3
doi:10.1158/2767-9764.CRC-25-0361
Powderly, John; Imbimbo, Martina; Italiano, Antoine; Martin-Romano, Patricia; McKean, Meredith; Macarulla, Teresa; Castañón Alvarez, Eduardo; Carneiro, Benedito A; Mager, Raymond; Barnhart, Vicky; Eck, Steven; Murtomaki, Elina; Loembé, Arsène-Bienvenu; He, Yun; Cooper, Zachary A; Tu, Eric; Fan, Chunling; Boyer Chamard, Agnes; Paturel, Carine; Fraenkel, Paula G; Hollebecque, Antoine
单克隆抗体
CD3
CD39
发表日期：2025
文献求助 收藏

Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study

托瑞普利单抗治疗胆管癌患者的安全性和有效性：一项开放标签的 I 期研究

期刊:Journal of Immunotherapy and Precision Oncology
影响因子:3.2
doi:10.36401/JIPO-24-8
Naing, Aung; Mahipal, Amit; Javle, Milind; Wang, Judy; Bauer, Todd M; Bajor, David L; Elias, Anthony D; Shields, Anthony; Davis, Elizabeth; Chawla, Sant; Safran, Howard; Powderly, John D; D'Amato, Gina; Meyer, Christian F; Tang, Xiongwen; Yao, Sheng; Keegan, Patricia
肿瘤
胆管癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Development of clinical research networks in rural America: Our experience from the Accelerating COVID-19 Therapeutic Interventions and Vaccines-1 trialau

美国农村地区临床研究网络的发展：我们从加速 COVID-19 治疗干预和疫苗-1 试验中汲取的经验

期刊:Journal of Clinical and Translational Science
影响因子:2
doi:10.1017/cts.2025.10208
Kedar, Eyal; Dandachi, Dima; Bryant, Alexis; Anstrom, Kevin J; Powderly, William
发表日期：2025
文献求助 收藏

Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors

IO-108（一种抗LILRB2抗体）治疗晚期实体瘤患者的I期剂量递增研究

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2024-010006
Taylor, Matthew H; Naing, Aung; Powderly, John; Woodard, Paul; Chung, Luke; Lin, Wen Hong; Tian, Hongyu; Siemers, Nathan; Xiang, Hong; Deng, Rong; Hong, Kyu; Valencia, Donna; Huang, Tao; Zhu, Ying; Liao, X Charlene; Schebye, Xiao Min; Patel, Manish R
发表日期：2024
文献求助 收藏

Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial

阿巴西普在新冠肺炎住院患者中的药代动力学和暴露反应：ACTIV-1 IM 随机临床试验的二次分析

期刊:Jama Network Open
影响因子:9.7
doi:10.1001/jamanetworkopen.2024.7615
Balevic, Stephen J; Benjamin, Daniel K Jr; Powderly, William G; Smith, P Brian; Gonzalez, Daniel; McCarthy, Matthew W; Shaw, Linda K; Lindsell, Christopher J; Bozzette, Sam; Williams, Daphne; Linas, Benjamin P; Blamoun, John; Javeri, Heta; Hornik, Christoph P
肺炎
新冠
微生物学
发表日期：2024
文献求助 收藏